RVMD
NASDAQ HealthcareRevolution Medicines, Inc. - Common Stock
Biotechnology
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
๐ Market Data
| Price | $194.18 |
|---|---|
| Volume | 595,437 |
| Market Cap | 41.60B |
| Beta | 1.410 |
| RSI (14-Day) | 28.4 Oversold |
| 200-Day MA | $141.55 |
| 50-Day MA | $199.54 |
| 52-Week High | $224.31 |
| 52-Week Low | $42.18 |
| Forward P/E | -32.26 |
| Price / Book | 15.95 |
๐ฏ Investment Strategy Scores
RVMD scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Institutional Whale (83/100) โ this strategy Large-cap, institutional-quality stocks.
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (19/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find RVMD in your text
Paste any article, transcript, or post โ the tool will extract RVMD and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-24.